US Pharmaceuticals Ishares ETF (IHE)

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

Merck & Co. has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.